NFX

Nuformix further evaluating NXP002 combination therapies now underway

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of..

February 15, 2023

Nuformix delighted with NXP004 results which exceeded expectations

December 20, 2022

Nuformix excited by prospects for the remainder of the year

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its unaudited results for the six months ended 30 September 2022. Operational highlights..

December 13, 2022

Nuformix investor webinar Wednesday 9th November 2022

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company will be hosting an online presentation and..

November 4, 2022

Nuformix lead programme introduced to major respiratory players (VIDEO)

September 23, 2022

Nuformix report NXP002 successful completion of tolerability studies

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that NXP002, a new form of tranilast and a potential..

August 10, 2022

Nuformix to continue to optimise value of assets

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced its audited results for the year ended 31 March 2022. Non-executive..

July 28, 2022

Nuformix NXP002 data to be presented at 2022 ERS Congress

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that both of the abstracts submitted for presentation at the..

July 5, 2022

Nuformix scale-up of lead cocrystal production processes

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has provided an update in relation to the Company’s NXP004 programme, focused..

June 29, 2022

Nuformix to investigate a new formulation of NXP002

June 27, 2022

Nuformix provides an update on Company’s assets and other corporate matters

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has provided an update on the Company’s assets and other corporate matters. NXP002..

May 30, 2022

Nuformix second tranche of Lanstead subscription shares

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that further to the notifications of 14 December 2021 and 17..

April 12, 2022

Nuformix first patent in relation to NXP004 to the publication stage

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the publication of an international patent in relation to the..